Bharat Parenterals Ltd on Friday, November 28, announced that its subsidiary Innoxel Lifesciences has successfully completed the European Union Good Manufacturing Practice (EU-GMP) inspection conducted by Belgium’s Federal Agency for Medicines and Health Products (FAMHP).
According to the company’s exchange filing, the audit was carried out at Innoxel’s manufacturing facility in Vadodara, Gujarat, between November 24 and November 28, 2025. The inspection concluded with zero critical and zero major observations, underscoring the company’s strong compliance framework and adherence to global regulatory standards.
The successful EU-GMP inspection adds to Innoxel’s regulatory milestones, following its earlier positive outcomes in USFDA inspections. Management said the development strengthens the company’s position as a reliable global manufacturing partner and supports its long-term international growth strategy.
Bharat Parenterals stated that both the parent company and its subsidiary will continue investing in quality systems and regulatory processes as they expand their footprint in regulated markets worldwide.
